Of note, it was shown that the combination of the GLP1-RA Liraglutide with the flavonoid quercetin in an in vivo diabesity experimental model significantly decreased the total cholesterol and triglyceride blood levels in the treated rats and, in addition, significantly reduced the HOMA-IR index, indicating that the combination of quercetin with the anti-obesity drug Liraglutide can inhibit the insulin resistance mechanisms that play a role in obesity development [118]. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.